Bharat Biotech, which is developing a vaccine for coronavirus in collaboration with Indian Council of Medical Research (ICMR), has said that it will be ready by June 2021. The Hyderabad-based vaccine maker recently got a nod for late-stage human trials for its Covid vaccine candidate Covaxin.
According to a company official, the vaccine could be available in market even before that if government advances its launch through emergency use authorization. Over20,000 volunteers across 12-14 states will be tested during the phase 3 trials, whose results will determine the launch of the vaccine. In case of full efficacy results, the vaccine is likely to be launched in Q2 of next year, the official added.
Covaxin, which is being developed in collaboration with National Institute of Virology is an activated vaccine. During the vaccination process, killed version of covid19 will be injected into the body in order to develop an immune response.
In an interview with a newspaper, Sai Prasad, executive director, Bharat Biotech International Ltd said that the company wants to conduct all trials properly and would not push for approval. However, if government considers emergency use approval, the launch might be advanced. He said the company plans to establish 25 clincal trial sites across 12-14 states of the country. He said that the site selection for phase-3 trials will be different from that of phase-1 and phase-2 trials and new states might be added on to the list.
Serum Institute of India, which is preparing a vaccine in collaboration with University of Oxford and AstraZeneca is currently the front-runner in the race for vaccine, According to reports, the institute is in the process of recruiting and vaccinating volunteers for phase-3 trials.
Meanwhile, cases in India have crossed 78-lakh mark. Maharashtra, Kerala and Karnataka remain the worst-affected states in the country.